NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $62.26 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$62.28 +0.02 (+0.04%) As of 05/22/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tarsus Pharmaceuticals Stock (NASDAQ:TARS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tarsus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$62.17▼$65.0850-Day Range$59.65▼$73.8152-Week Range$38.51▼$85.25Volume259,588 shsAverage Volume765,222 shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/APrice Target$90.67Consensus RatingModerate Buy Company Overview Tarsus Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life. In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders. The company leverages a multidisciplinary pipeline strategy, combining small‐molecule drug discovery with novel delivery approaches to optimize tissue penetration and minimize systemic exposure. Tarsus collaborates with clinical research sites across North America and Europe to execute its global development plans and intends to explore strategic partnerships for later‐stage commercialization and distribution. Founded in 2018 and headquartered in Westlake Village, California, Tarsus Pharmaceuticals was established by a team of industry veterans with deep experience in ophthalmology, neurology and pharmaceutical development. The company’s leadership team includes seasoned executives with track records in launching ophthalmic products and navigating regulatory pathways. Tarsus maintains corporate offices in the United States and engages with regulatory authorities to advance its portfolio toward potential approval and market launch.AI Generated. May Contain Errors. Read More Tarsus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreTARS MarketRank™: Tarsus Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 235th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 2 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTarsus Pharmaceuticals has a consensus price target of $90.67, representing about 45.6% upside from its current price of $62.26.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($0.59) to $2.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -54.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -54.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.39% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 5.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.70 News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Tarsus Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for TARS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,432,035.00 in company stock.Percentage Held by Insiders9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Stock News HeadlinesTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 12th. | Banyan Hill Publishing (Ad)Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comCena was diagnosed with Demodex blepharitis, which he admittedly "didn't even know existed"May 14, 2026 | yahoo.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansMay 14, 2026 | globenewswire.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsMay 13, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $81.88 at the start of the year. Since then, TARS stock has decreased by 24.0% and is now trading at $62.26. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.24. The firm earned $162.05 million during the quarter, compared to analysts' expectations of $149.60 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 14.19% and a negative net margin of 9.02%. Read the conference call transcript. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $88 million in an initial public offering on Friday, October 16th 2020. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' top institutional shareholders include Janus Henderson Group PLC (5.21%), Jennison Associates LLC (3.98%), Assenagon Asset Management S.A. (3.01%) and Bank of America Corp DE (2.78%). Insiders that own company stock include William J Phd Link, Seshadri Neervannan, Bryan Wahl, Aziz Mottiwala, Jeffrey S Farrow, Dianne C Whitfield, Bobak R Azamian, Elizabeth Yeu Lin, Andrew D Goldberg and Jose M Trevejo. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tarsus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2026Today5/25/2026Stifel 2026 Virtual Ophthalmology Forum5/26/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 13 days, TARS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARS CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees50Year Founded2017Price Target and Rating Average Price Target for Tarsus Pharmaceuticals$90.67 High Price Target$100.00 Low Price Target$68.00 Potential Upside/Downside+45.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.42 million Net Margins-9.02% Pretax Margin-7.33% Return on Equity-14.19% Return on Assets-8.89% Debt Debt-to-Equity Ratio0.21 Current Ratio3.74 Quick Ratio3.71 Sales & Book Value Annual Sales$451.36 million Price / Sales5.93 Cash FlowN/A Price / Cash FlowN/A Book Value$8.11 per share Price / Book7.68Miscellaneous Outstanding Shares43,020,000Free Float38,876,000Market Cap$2.68 billion OptionableOptionable Beta0.52 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TARS) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
